Justin Skoble, Ph.D.
Affiliations: | 2001 | University of California, Berkeley, Berkeley, CA, United States |
Area:
Molecular and cellular basis of microbial pathogenesisGoogle:
"Justin Skoble"Parents
Sign in to add mentor| Daniel Portnoy | grad student | 2001 | UC Berkeley | |
| (Mechanism of actin nucleation by the Listeria monocytogenes ActA protein.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Hanson WG, Benanti EL, Lemmens EE, et al. (2019) A potent and effective suicidal vaccine platform. Infection and Immunity |
| Rae CS, Besprozvannaya M, Faulhaber J, et al. (2019) Abstract 4782: STACT: A novel tumor-targeting, systemically-administered delivery platform capable of targeting intractable pathways and precise immunomodulation of the tumor microenvironment Cancer Research. 79: 4782-4782 |
| Makarova AM, Iannello A, Rae CS, et al. (2019) Abstract 5016: STACT-TREX1: A systemically-administered STING pathway agonist targets tumor-resident myeloid cells and induces adaptive anti-tumor immunity in multiple preclinical models Cancer Research. 79: 5016-5016 |
| Le DT, Wang-Gillam A, Picozzi V, et al. (2015) Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: 1325-33 |
| Le DT, Wang-Gillam A, Picozzi VJ, et al. (2015) A phase 2b, randomized, controlled, multicenter, open-label study of the efficacy and immune response of GVAX pancreas vaccine and CRS-207 compared to chemotherapy or to CRS-207 alone in adults with previously treated metastatic pancreatic adenocarcinoma (ECLIPSE Study) F1000research. 6 |
| Le DT, Wang-Gillam A, Picozzi VJ, et al. (2015) A phase IIb, randomized, controlled, multicenter, open-label study of the efficacy and immune response of GVAX pancreas vaccine and CRS-207 compared to chemotherapy or to CRS-207 alone in adults with previously treated metastatic pancreatic adenocarcinoma (ECLIPSE Study). Journal of Clinical Oncology. 33: TPS489-TPS489 |
| Crittenden M, Bahjat KS, Li R, et al. (2015) Phase I study of safety and immunogenicity of ADU-623, a live-attenuated Listeria monocytogenes vaccine (ΔactA/ΔinlB) expressing EGFRvIII and NY-ESO-1, in patients with WHO grade III/IV astrocytomas. Journal of Clinical Oncology. 33 |
| Crittenden M, Bahjat KS, Li R, et al. (2015) Phase I study of safety and immunogenicity of ADU-623, a live-attenuated listeria monocytogenes vaccine (ΔactA/ΔinlB) expressing EGFRVIII and NY-ESO-1, in patients with who grade III/IV astrocytomas Journal For Immunotherapy of Cancer. 3: 162 |
| Wang-Gillam A, Picozzi V, Crocenzi T, et al. (2014) A Phase IIb, randomized, multicenter study of the efficacy of GVAX pancreas vaccine and CRS-207 compared to chemotherapy or to CRS-207 alone... Journal For Immunotherapy of Cancer. 2: 68 |
| Le DT, Wang-Gillam A, Picozzi, et al. (2014) A phase 2, randomized trial of GVAX pancreas and CRS-207 immunotherapy versus GVAX alone in patients with metastatic pancreatic adenocarcinoma: Updated results. Journal of Clinical Oncology. 32: 177-177 |